193 related articles for article (PubMed ID: 25443512)
1. Sterile compounding: clinical, legal, and regulatory implications for patient safety.
Qureshi N; Wesolowicz L; Stievater T; Lin AT
J Manag Care Spec Pharm; 2014 Dec; 20(12):1183-91. PubMed ID: 25443512
[TBL] [Abstract][Full Text] [Related]
2. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
[TBL] [Abstract][Full Text] [Related]
3. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
[TBL] [Abstract][Full Text] [Related]
4. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
Pinkerton JV; Pickar JH
Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
[TBL] [Abstract][Full Text] [Related]
5. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(41):839-42. PubMed ID: 23076093
[TBL] [Abstract][Full Text] [Related]
6. Fungal infections associated with contaminated methylprednisolone injections.
Smith RM; Schaefer MK; Kainer MA; Wise M; Finks J; Duwve J; Fontaine E; Chu A; Carothers B; Reilly A; Fiedler J; Wiese AD; Feaster C; Gibson L; Griese S; Purfield A; Cleveland AA; Benedict K; Harris JR; Brandt ME; Blau D; Jernigan J; Weber JT; Park BJ;
N Engl J Med; 2013 Oct; 369(17):1598-609. PubMed ID: 23252499
[TBL] [Abstract][Full Text] [Related]
7. Potential risks of pharmacy compounding.
Gudeman J; Jozwiakowski M; Chollet J; Randell M
Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
[TBL] [Abstract][Full Text] [Related]
8. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12.
Staes C; Jacobs J; Mayer J; Allen J
Am J Health Syst Pharm; 2013 Aug; 70(15):1301-12. PubMed ID: 23867487
[TBL] [Abstract][Full Text] [Related]
9. Fungal meningitis from injection of contaminated steroids: a compounding problem.
Wilson LE; Blythe D; Sharfstein JM
JAMA; 2012 Dec; 308(23):2461-2. PubMed ID: 23104261
[No Abstract] [Full Text] [Related]
10. Fungal infections associated with contaminated methylprednisolone in Tennessee.
Kainer MA; Reagan DR; Nguyen DB; Wiese AD; Wise ME; Ward J; Park BJ; Kanago ML; Baumblatt J; Schaefer MK; Berger BE; Marder EP; Min JY; Dunn JR; Smith RM; Dreyzehner J; Jones TF;
N Engl J Med; 2012 Dec; 367(23):2194-203. PubMed ID: 23131029
[TBL] [Abstract][Full Text] [Related]
11. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
[TBL] [Abstract][Full Text] [Related]
12. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned.
Shehab N; Brown MN; Kallen AJ; Perz JF
J Patient Saf; 2018 Sep; 14(3):164-173. PubMed ID: 26001553
[TBL] [Abstract][Full Text] [Related]
13. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
Hinkley KN
State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
[No Abstract] [Full Text] [Related]
14. Survey of sterile product compounding practices in Canadian hospital pharmacies.
Fitch DP; Hall KW
Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
[TBL] [Abstract][Full Text] [Related]
15. Improving the Quality of Compounded Sterile Drug Products: A Historical Perspective.
Cantrell SA
Ther Innov Regul Sci; 2016 May; 50(3):266-269. PubMed ID: 30227062
[TBL] [Abstract][Full Text] [Related]
16. CDC probes new outbreak associated with compounded steroids.
Kuehn BM
JAMA; 2013 Jun; 309(24):2541. PubMed ID: 23800915
[No Abstract] [Full Text] [Related]
17. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
[TBL] [Abstract][Full Text] [Related]
18. Clinical findings for fungal infections caused by methylprednisolone injections.
Chiller TM; Roy M; Nguyen D; Guh A; Malani AN; Latham R; Peglow S; Kerkering T; Kaufman D; McFadden J; Collins J; Kainer M; Duwve J; Trump D; Blackmore C; Tan C; Cleveland AA; MacCannell T; Muehlenbachs A; Zaki SR; Brandt ME; Jernigan JA;
N Engl J Med; 2013 Oct; 369(17):1610-9. PubMed ID: 24152260
[TBL] [Abstract][Full Text] [Related]
19. Toward Better-Quality Compounded Drugs - An Update from the FDA.
Woodcock J; Dohm J
N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
[No Abstract] [Full Text] [Related]
20. Regulating compounding pharmacies after NECC.
Outterson K
N Engl J Med; 2012 Nov; 367(21):1969-72. PubMed ID: 23134357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
